Data as of · Health Care sector.
Forecast: StoQuant's ML model estimates a 71% probability that VERTEX PHARMACEUTICALS INC (VRTX) outperforms the S&P 500 over the next 90 trading days — a bullish signal. Wall Street's consensus 12-month price target is $548.17 from 6 analyst targets.
ML Forecast (90-day)
71% bullish
Probability of beating the S&P 500 over the next 90 trading days
Q-Score
53/100
Grade C — "Hold" composite of 140+ signals
Analyst Target
$548.17
6 targets · $460.00–$578.56
Next Earnings
2026-11-02
in 50 days — expect volatility
The ML model scores VRTX on 57 live features, trained on 5,328 labeled outcomes and walk-forward validated. Biggest drivers of today's bullish call:
Across 6 price targets published in the last 90 days (latest 2026-09-04), the consensus for VERTEX PHARMACEUTICALS INC is $548.17 — spanning $460.00 on the low end to $578.56 on the high end.
Next-period consensus: EPS n/a (as of 2030-12-31).
StoQuant publishes its full walk-forward accuracy, updated daily. Current hit rates across all scored signals:
| Signal | Window | Hit rate | Avg return | Observations |
|---|---|---|---|---|
| Fundamental Undervalue | 7d | 51.1% | +0.50% | 9,340 |
| Vc Intelligence | 7d | 50.0% | +0.72% | 18 |
| Volume Spike | 7d | 49.1% | +0.23% | 6,275 |
| Sector Momentum | 7d | 48.5% | +0.02% | 16,414 |
See the full live track record → · How the model works
⚠ VERTEX PHARMACEUTICALS INC reports earnings on 2026-11-02 — expect elevated volatility and a forecast refresh right after the report.
Similar stocks to VRTX for comparison and diversification research:
Compare VRTX vs AZN head-to-head →
AAPL MSFT NVDA GOOGL GOOG AMZN META TSLA AVGO LLY JPM V WMT XOM UNH MA COST ORCL HD NFLX
Discover other stocks and tools:
StoQuant's ML model estimates a 71% probability that VERTEX PHARMACEUTICALS INC (VRTX) outperforms the S&P 500 over the next 90 trading days — a bullish signal. Wall Street's consensus 12-month price target is $548.17 from 6 analyst targets.
StoQuant's Q-Score rates VRTX 53/100 (grade C, "Hold") and the 90-day ML signal is bullish at 71% probability. StoQuant publishes its full walk-forward track record at /proof — always check a forecaster's accuracy before acting.
The consensus analyst price target for VERTEX PHARMACEUTICALS INC is $548.17, with a range of $460.00 to $578.56 across 6 recent analyst targets.
Across StoQuant's walk-forward validated signal history, the fundamental undervalue signal hit its 7-day target in 51.1% of 9,340 observations (avg return +0.50%). Full methodology and live accuracy at /proof.
VERTEX PHARMACEUTICALS INC is scheduled to report earnings on 2026-11-02. Expect elevated forecast volatility around the report.
MSFT · AAPL · NVDA · GOOGL · META · TSLA · AMD · INTC · QCOM · AVGO
BRK.B · JPM · V · MA · WMT · PG · JNJ · XOM · UNH · HD
COST · MCD · NFLX · DIS · PFE · ABBV · TMO · CRM · ADBE
BAC · WFC · GS · MS · CVX · COP · UBER · AMAT · MU
Get VRTX's forecast refreshed daily — plus the full signal stack.
ML forecasts, Q-Scores, insider clusters, and catalysts across 4,000+ tickers. Free screener.
Open the free screener Full VRTX researchTrack record · Methodology · All forecasts · VRTX deep dive
Forecasts are probabilistic model outputs, not investment advice. Past accuracy does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.